POINT: FY2023 EPS Estimates for POINT Biopharma Global Inc. Lifted by Analyst (NASDAQ:PNT)

POINT Biopharma Global Inc. ( NASDAQ:PNT - Free Report ) - Stock analysts at William Blair lifted their FY2023 earnings per share (EPS) estimates for shares of POINT Biopharma Global in a research report issued to clients and investors on Monday, November 13th. William Blair analyst A. Hsieh now expects that the company will post earnings of $0.95 per share for the year, up from their previous forecast of ($1.03). William Blair has a "Market Perform" rating on the stock. The consensus estimate for POINT Biopharma Global's current full-year earnings is ($1.00) per share. William Blair also issued estimates for POINT Biopharma Global's FY2024 earnings at ($1.40) EPS. Other equities analysts have also recently issued research reports about the company. Raymond James cut POINT Biopharma Global from an "outperform" rating to a "market perform" rating and decreased their price target for the stock from $13.00 to $12.50 in a report on Thursday, October 5th. SVB Leerink lowered POINT Biopharma Global from an "outperform" rating to a "market perform" rating in a research report on Friday, October 6th. Jefferies Financial Group lowered POINT Biopharma Global from a "buy" rating to a "hold" rating in a research report on Tuesday, October 3rd. Jonestrading reissued a "hold" rating on shares of POINT Biopharma Global in a research report on Wednesday, October 4th. Finally, Truist Financial lowered POINT Biopharma Global from a "buy" rating to a "hold" rating and dropped their price target for the company from $13.00 to $12.50 in a research report on Tuesday, October 3rd. Nine analysts have rated the stock with a hold rating, According to data from MarketBeat, the company has an average rating of "Hold" and an average price target of $13.42. POINT Biopharma Global Stock Down 0.5 % NASDAQ PNT opened at $13.33 on Thursday. The stock has a market cap of $1.41 billion, a PE ratio of 14.81 and a beta of -0.05. POINT Biopharma Global has a fifty-two week low of $5.95 and a fifty-two week high of $13.55. The business has a 50 day moving average price of $10.87 and a two-hundred day moving average price of $9.67. The company has a quick ratio of 10.51, a current ratio of 10.51 and a debt-to-equity ratio of 0.01. POINT Biopharma Global ( NASDAQ:PNT - Get Free Report ) last issued its earnings results on Monday, November 13th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.30) by $0.07. POINT Biopharma Global had a return on equity of 20.60% and a net margin of 39.62%. The business had revenue of $2.79 million during the quarter, compared to analysts' expectations of $8.00 million. Institutional Investors Weigh In On POINT Biopharma Global Several large investors have recently added to or reduced their stakes in PNT. Qube Research & Technologies Ltd grew its stake in shares of POINT Biopharma Global by 329.8% in the third quarter. Qube Research & Technologies Ltd now owns 117,587 shares of the company's stock worth $784,000 after purchasing an additional 90,230 shares in the last quarter. Profund Advisors LLC grew its stake in shares of POINT Biopharma Global by 5.5% in the third quarter. Profund Advisors LLC now owns 38,551 shares of the company's stock worth $257,000 after purchasing an additional 1,996 shares in the last quarter. Northern Trust Corp grew its stake in shares of POINT Biopharma Global by 2.6% in the third quarter. Northern Trust Corp now owns 822,026 shares of the company's stock worth $5,483,000 after purchasing an additional 20,832 shares in the last quarter. Invesco Ltd. grew its stake in shares of POINT Biopharma Global by 111.8% in the third quarter. Invesco Ltd. now owns 132,977 shares of the company's stock worth $887,000 after purchasing an additional 70,196 shares in the last quarter. Finally, WINTON GROUP Ltd bought a new position in shares of POINT Biopharma Global in the third quarter worth $107,000. 59.53% of the stock is owned by institutional investors and hedge funds. POINT Biopharma Global Company Profile ( Get Free Report ) POINT Biopharma Global Inc, a radiopharmaceutical company, develops and commercializes radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. Featured Articles Five stocks we like better than POINT Biopharma Global Insider Trades May Not Tell You What You Think Amazon, Target, Walmart in a race for fastest delivery What is the NASDAQ Stock Exchange? Palo Alto Networks: the one security stock to rule them all How to Invest in Insurance Companies: A Guide Is it time to buy the dip in Walmart shares? Receive News & Ratings for POINT Biopharma Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for POINT Biopharma Global and related companies with MarketBeat.com's FREE daily email newsletter .